Skip to main content
Premium Trial:

Request an Annual Quote

Roche Licenses Codexis DNA Ligase Enzyme for NGS Library Prep Kits

NEW YORK – Codexis announced Monday an agreement to license its EvoT4 DNA ligase enzyme to Roche.

The firm said it expects Roche to incorporate the enzyme in next-generation sequencing library preparation kits and other sequencing products.

Under the terms of the license, Roche gained worldwide rights to include EvoT4 DNA ligase in its nucleic acid sequencing products and workflows. Roche will pay Codexis royalties; other financial details were not disclosed. 

"We are very excited to license our first product targeting this market to Roche Sequencing Solutions. This deal underscores our belief in genomic sequencing as an attractive commercial target for our company, and we look forward to future successful introductions of additional CodeEvolver-derived innovations in this and other Life Science applications," Codexis CEO and President John Nicols said in a statement.

Codexis, a Redwood City, California-based protein engineering company, developed the EvoT4 enzyme to improve the efficiency and speed of adapter ligation for low-input DNA samples.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.